Treatment of hepatitis C with daily induction dose interferon alpha 2b plus ribavirin followed by daily combination therapy in patients who are treatment naive or have previously failed an interferon based therapy.

被引：0
|
作者：
Lawitz, EJ [1 ]
Kadakia, SC [1 ]
Cantu, N [1 ]
Nader, P [1 ]
Cox, J [1 ]
Ganeshappa, KP [1 ]
Reddy, G [1 ]
Nguyen, TT [1 ]
Diamond, K [1 ]
Lindner, M [1 ]
Ostower, V [1 ]
Vemura, R [1 ]
机构：
[1] Brooke Army Med Ctr, San Antonio, TX USA
来源：
GASTROENTEROLOGY | 2000年 / 118卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(00)81746-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
6625
引用
收藏
页码：A1462 / A1462
页数：1
相关论文
共 50 条
  • [21] Alpha-interferon plus ribavirin for the treatment of chronic hepatitis C in patients who have failed treatment with alpha-interferon.
    Kwo, PY
    Pound, DC
    Fields, S
    Glowinski, EA
    Chalasani, N
    Cho, WK
    Crabb, DW
    Cummings, OW
    Imperiale, T
    Lumeng, L
    McGill, JM
    Ness, R
    HEPATOLOGY, 1999, 30 (04) : 368A - 368A
  • [22] High dose induction therapy with consensus interferon followed by combination therapy with ribavirin for treatment-naive patients with chronic hepatitis C.
    Kaiser, S
    Kreysel, C
    Gregor, M
    HEPATOLOGY, 2000, 32 (04) : 561A - 561A
  • [23] Interferon-alpha and ribavirin alone or in combination with ketoprofen for the treatment of patients with chronic hepatitis C who have not responded to previous interferon therapy.
    Nunes, FA
    Schultz, C
    Santoro, J
    Kaufman, B
    Kenny, R
    Rock, E
    Gasic, A
    Carlson, S
    Griffell, L
    Shields, D
    Matasow, G
    Lucey, MR
    HEPATOLOGY, 1999, 30 (04) : 617A - 617A
  • [24] Interferon-alpha and ribavirin alone or in combination with ketoprofen for the treatment of patients with chronic hepatitis C who have not responded to previous interferon therapy.
    Nunes, FA
    Santoro, J
    Kaufman, B
    Kenny, R
    Rock, E
    Gasic, A
    Carlson, S
    Griffel, L
    Shields, D
    Matusow, G
    O'Toole, W
    Brass, CA
    Lucey, MR
    HEPATOLOGY, 1998, 28 (04) : 579A - 579A
  • [25] Daily administration of interferon alpha 2B and utility of combination therapy with ribavirin as initial treatment for chronic hepatitis C: Follow up of patients.
    Ricchiuti, A
    Ciccorossi, P
    Costa, F
    Bellini, M
    Carrara, PD
    Arpe, P
    Petruccelli, S
    Maggi, F
    Vatteroni, ML
    Bendinelli, M
    Maltinti, G
    Marchi, S
    HEPATOLOGY, 2000, 32 (04) : 366A - 366A
  • [26] Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine
    Rudolf E Stauber
    Harald Hofer
    Franz Hackl
    Kurt Schüze
    Christian Datz
    Karin Hegenbarth
    Wolfgang Jessner
    Petra Steindl-Munda
    Peter Ferenci
    Wiener Klinische Wochenschrift, 2004, 116 : 530 - 535
  • [27] Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine
    Stauber, RE
    Hofer, H
    Hackl, F
    Schütze, K
    Datz, C
    Hegenbarth, K
    Jessner, W
    Steindl-Munda, P
    Ferenci, P
    WIENER KLINISCHE WOCHENSCHRIFT, 2004, 116 (15-16) : 530 - 535
  • [28] PEG-Interferon α-2b+ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virologic response following interferon alfa or interferon a-2b+ribavirin therapy.
    Sulkowski, M
    Rothstein, K
    Stein, L
    Godofsky, E
    Goodman, R
    Dieterich, D
    GASTROENTEROLOGY, 2003, 124 (04) : A783 - A783
  • [29] Effectiveness of Interferon α-2b and Ribavirin Combination Therapy in the Treatment of Naive Chronic Hepatitis C Patients in Clinical Practice
    Shehab, Thomas M.
    Fontana, Robert J.
    Oberhelman, Kelly
    Marrero, Jorge A.
    Su, Grace L.
    Lok, Anna S. F.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (05) : 425 - 431
  • [30] Prediction of response to retreatment with interferon alfa 2B in chronic hepatitis C patients who previously failed 24 weeks of interferon alpha therapy.
    Tong, M
    Blatt, LM
    Tong, L
    Sayadzadeh, K
    Conrad, A
    GASTROENTEROLOGY, 1998, 114 (04) : A1355 - A1355
12345